Theravance, Inc. (NASDAQ:THRX) has announced that they have received a US$20 million milestone payment after their new drug telavancin was approved by the Food and Drug Administration panel. In September 2009, FDA approved the telavancin injection which can be given once daily to patients suffering from complicated skin and skin structure infections that is caused by susceptible Gram positive bacteria. Approval of telavancin was based on data from 2 double-blind randomized Phase 3 trial where telavancin marketed as Vibativ demonstrated its efficacy and safety in clinical trials on patients suffering from various skin structure infections and strains. Although, Vibativ clearly got a green signal from the FDA panel there were some adverse reactions which were registered like taste disturbance, vomiting, nausea and foamy urine.
http://www.favstocks.com/theravance-mile...